Zobrazeno 1 - 10 of 213 pro vyhledávání: '"Zachary A Cooper"'
3
Akademický článek
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
Autor: Christopher Morehouse, Rakesh Kumar, Antoine Hollebecque, Aurélien Marabelle, Zachary A Cooper, Joshua Brody, Farzana Walcott, Charles Ferte, Shilpa Gupta, David S Hong, Lillian Siu, Antonio Jimeno, Pamela Munster, Juneko Grilley-Olson, Alain H Rook, Rebecca K S Wong, James W Welsh, Yuling Wu, Oday Hamid
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background MEDI9197 is an intratumorally administered toll-like receptor 7 and 8 agonist. In mice, MEDI9197 modulated antitumor immune responses, inhibited tumor growth and increased survival. This first-time-in-human, phase 1 study evaluated MEDI919
Externí odkaz: https://doaj.org/article/1cea92e961774c018a7c1b71c547d92b
Zobrazit plný text záznamu
4
Akademický článek
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
Autor: Michael P Smith, Emily J Rowling, Zsofia Miskolczi, Jennifer Ferguson, Loredana Spoerri, Nikolas K Haass, Olivia Sloss, Sophie McEntegart, Imanol Arozarena, Alex von Kriegsheim, Javier Rodriguez, Holly Brunton, Jivko Kmarashev, Mitchell P Levesque, Reinhard Dummer, Dennie T Frederick, Miles C Andrews, Zachary A Cooper, Keith T Flaherty, Jennifer A Wargo, Claudia Wellbrock
Publikováno v: EMBO Molecular Medicine, Vol 9, Iss 8, Pp 1011-1029 (2017)
Abstract Approaches to prolong responses to BRAF targeting drugs in melanoma patients are challenged by phenotype heterogeneity. Melanomas of a “MITF‐high” phenotype usually respond well to BRAF inhibitor therapy, but these melanomas also conta
Externí odkaz: https://doaj.org/article/7cabb6c3861544079d79157438ec0d09
Zobrazit plný text záznamu
5
Akademický článek
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
Autor: Adam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, Subash Baniya, Zachary A Cooper, Adriano Piris, Leeza Hargreaves, Vivien Igras, Dennie T Frederick, Donald P Lawrence, Daniel A Haber, Keith T Flaherty, Jennifer A Wargo, Sridhar Ramaswamy, Cyril H Benes, David E Fisher
Publikováno v: PLoS ONE, Vol 10, Iss 10, p e0140310 (2015)
A newer generation of anti-cancer drugs targeting underlying somatic genetic driver events have resulted in high single-agent or single-pathway response rates in selected patients, but few patients achieve complete responses and a sizeable fraction o
Externí odkaz: https://doaj.org/article/2c65cc61a9ae4bf8a9a2e40f9c38d289
Zobrazit plný text záznamu
6
Akademický článek
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.
Autor: Dennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, Isabel Ferreiro-Neira, Taylor Hoff, Zachary A Cooper, Rizwan Haq, David J Panka, Lawrence N Kwong, Michael A Davies, James C Cusack, Keith T Flaherty, David E Fisher, James W Mier, Jennifer A Wargo, Ryan J Sullivan
Publikováno v: PLoS ONE, Vol 9, Iss 7, p e101286 (2014)
While response rates to BRAF inhibitiors (BRAFi) are high, disease progression emerges quickly. One strategy to delay the onset of resistance is to target anti-apoptotic proteins such as BCL-2, known to be associated with a poor prognosis. We analyze
Externí odkaz: https://doaj.org/article/8814805ec5d04e5395a5f296e5e3124d
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje